COVID-19 in-hospital mortality and use of renin-angiotensin system blockers in geriatrics patients.

[1]  Qingbo Xu,et al.  In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 , 2020, Cell Metabolism.

[2]  C. Torp‐Pedersen,et al.  Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. , 2020, JAMA.

[3]  R. Dobson,et al.  The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents , 2020, Journal of the American Medical Directors Association.

[4]  P. Serruys,et al.  Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[5]  Sun-Young Jung,et al.  Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Rodríguez-Mañas,et al.  Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.

[7]  J. Batsis,et al.  There is a Relationship Between Obesity and Coronavirus Disease 2019 but More Information is Needed , 2020, Obesity.

[8]  C. Specchia,et al.  Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy , 2020, European heart journal.

[9]  G. Mancia,et al.  Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.

[10]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[11]  L. Tavazzi,et al.  The battle against COVID-19: mortality in Italy , 2020, European heart journal.

[12]  Junyan Han,et al.  Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension , 2020, Hypertension.

[13]  Jian Chen,et al.  Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.

[14]  Qingbo Xu,et al.  Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.

[15]  J. Saavedra.  Angiotensin receptor blockers and COVID-19 , 2020, Pharmacological Research.

[16]  Ji-Guang Wang,et al.  Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 , 2020, Cardiovascular research.

[17]  Chang Hu,et al.  Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, Journal of Clinical Virology.

[18]  L. Calvó-Perxas,et al.  CAUSES, mortality rates and risk factors of death in community-dwelling Europeans aged 50 years and over: Results from the Survey of Health, Ageing and Retirement in Europe 2013-2015. , 2020, Archives of gerontology and geriatrics.

[19]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[20]  Yuxin Shi,et al.  Clinical progression of patients with COVID-19 in Shanghai, China , 2020, Journal of Infection.

[21]  Kai Liu,et al.  Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients , 2020, Journal of Infection.

[22]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[23]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[24]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. Deb,et al.  Risk Factors for Long-term Mortality and Patterns of End-of-Life Care Among Medicare Sepsis Survivors Discharged to Home Health Care , 2020, JAMA network open.

[26]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[27]  B. Guidet,et al.  Effect of Systematic Intensive Care Unit Triage on Long-term Mortality Among Critically Ill Elderly Patients in France: A Randomized Clinical Trial , 2017, JAMA.

[28]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[29]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[30]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[31]  T. Marrie.  Community-acquired pneumonia in the elderly. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.